Urology Department, Federative Pelvic Pain Center, Nantes University Hospital, 44093 Nantes, France.
Department of Gynecology-Obstetrics and Reproductive Medicine, Federative Pelvic Pain Center, 44000 Nantes University Hospital, Nantes, France.
Ann Phys Rehabil Med. 2021 Jan;64(1):101354. doi: 10.1016/j.rehab.2019.12.009. Epub 2020 Jan 22.
Many studies have demonstrated a link between pelvic floor myofascial syndromes and chronic pelvic pain. Botulinum toxin has been extensively used for several years in the field of pain, especially due to its action on muscle spasm. However, the efficacy of botulinum toxin in the context of chronic pelvic pain remains controversial.
This multicentre, randomized, controlled, double-blind study was designed to compare the efficacy of botulinum toxin and local anaesthetic (LA) injection versus LA injection alone for pelvic floor myofascial syndrome and chronic pelvic pain.
According to the number of painful trigger points detected on physical examination, patients received from 1 to 4 injections of botulinum toxin with LA (BTX) or LA alone. The primary endpoint was Patient Global Impression of Improvement (PGI-I) score on day 60 after infiltration. Secondary endpoints were pain intensity, number of painful trigger points on palpation, analgesic drug consumption and quality of life.
We included 80 patients, 40 in each group. This study failed to demonstrate a significant difference between the 2 groups on day 60 in the primary endpoint or secondary endpoints (PGI-I score≤2=20% [LA] versus 27.5% [BTX], P=0.43). However, both groups showed significant alleviation of global pain.
This study does not justify the use of botulinum toxin in the context of chronic pelvic pain with myofascial syndrome but does justify muscle injections with LA alone. ClinicalTrials.gov: NCT01967524.
许多研究表明,盆底肌筋膜综合征与慢性盆腔痛之间存在关联。肉毒毒素在疼痛领域已经被广泛应用多年,尤其是由于其对肌肉痉挛的作用。然而,肉毒毒素在慢性盆腔痛中的疗效仍存在争议。
本多中心、随机、对照、双盲研究旨在比较肉毒毒素和局部麻醉剂(LA)注射与单独 LA 注射治疗盆底肌筋膜综合征和慢性盆腔痛的疗效。
根据体格检查中检测到的疼痛触发点数量,患者接受 1 至 4 次含有 LA 的肉毒毒素(BTX)或单独 LA 注射。主要终点是浸润后 60 天的患者总体改善印象(PGI-I)评分。次要终点是疼痛强度、触诊时的疼痛触发点数量、镇痛药物消耗和生活质量。
我们纳入了 80 名患者,每组 40 名。这项研究未能在 60 天的主要终点或次要终点(PGI-I 评分≤2=20%[LA]与 27.5%[BTX],P=0.43)上显示两组之间有显著差异。然而,两组的整体疼痛均有明显缓解。
本研究不能证明在伴有肌筋膜综合征的慢性盆腔痛中使用肉毒毒素是合理的,但可以证明单独使用 LA 进行肌肉注射是合理的。ClinicalTrials.gov:NCT01967524。